{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294892","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.231869+00:00","generated_at":"2026-06-07T12:45:51.333390+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apellis receives negative trend vote on EU MAA for pegcetacoplan; expects CHMP negative opinion in Jan 2024","bullets":["CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.","Apellis expects CHMP to adopt negative opinion at Jan 22-25, 2024 meeting.","Company plans to appeal and seek re-examination of the opinion.","Pegcetacoplan is for GA secondary to age-related macular degeneration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294892","json":"https://secwatch.observer/filing/0001193125-23-294892.json","markdown":"https://secwatch.observer/filing/0001193125-23-294892.md","text":"https://secwatch.observer/filing/0001193125-23-294892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523294892/0001193125-23-294892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312523294892/d863487d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:45:51.333390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}